-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$105.6219.24% Upside
Recent Analyst Forecasts and Stock Ratings
Blueprint Medicines Corporation Frequently Asked Questions
-
What analysts cover Blueprint Medicines Corporation?
Blueprint Medicines Corporation has been rated by research analysts at Stifel Nicolaus, Oppenheimer, Barclays, Leerink Partners, Raymond James, H.C. Wainwright in the past 90 days.